Yinmo Yang
Overview
Explore the profile of Yinmo Yang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
1043
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang E, Ma Y, Liu Z, Zhang J, Liu W, Chen Y, et al.
J Transl Med
. 2025 Mar;
23(1):301.
PMID: 40065365
Background: Pancreatic ductal adenocarcinoma (PDAC) is among the most aggressive cancers, with rising incidence and limited responsiveness to immunotherapy due to its highly suppressive tumor microenvironment (TME). Tertiary lymphoid structures...
2.
Tang H, Zhang W, Cao J, Cao Y, Bi X, Zhao H, et al.
Biosci Trends
. 2024 Dec;
18(6):505-524.
PMID: 39721704
Up to half of hepatocellular carcinoma (HCC) cases are diagnosed at an advanced stage, for which effective treatment options are lacking, resulting in a poor prognosis. Over the past few...
3.
Li D, Chu X, Liu W, Ma Y, Tian X, Yang Y
RNA Biol
. 2024 Dec;
22(1):1-14.
PMID: 39718205
The crosstalk between the tumour immune microenvironment (TIME) and tumour cells promote immune evasion and resistance to immunotherapy in gastrointestinal (GI) tumours. Post-transcriptional regulation of genes is pivotal to GI...
4.
Li D, Chu X, Ma Y, Zhang F, Tian X, Yang Y, et al.
Cancer Lett
. 2024 Dec;
611:217403.
PMID: 39709178
Pancreatic cancer (PC) is one of the most malignant solid cancers, and PC metastasis, particularly liver metastasis, is a major cause of cancer mortality. A key event in tumor metastasis...
5.
Zhang F, Ma Y, Li D, Wei J, Chen K, Zhang E, et al.
J Hematol Oncol
. 2024 Sep;
17(1):80.
PMID: 39223656
Metabolic reprogramming provides tumors with an energy source and biofuel to support their survival in the malignant microenvironment. Extensive research into the intrinsic oncogenic mechanisms of the tumor microenvironment (TME)...
6.
Chen K, Li T, Diao H, Wang Q, Zhou X, Huang Z, et al.
Cancer Lett
. 2024 Jul;
598:217109.
PMID: 39002692
Gemcitabine serves as a first-line chemotherapeutic treatment for pancreatic cancer (PC), but it is prone to rapid drug resistance. Increasing the sensitivity of PC to gemcitabine has long been a...
7.
Chu X, Zhong X, Zang S, Wang M, Li P, Ma Y, et al.
Front Oncol
. 2024 Jul;
14:1327280.
PMID: 38983932
Objective: The circulating tumor cells (CTCs) could be captured by the peptide functionalized magnetic nanoparticles (Pep@MNP) detection system in pancreatic ductal adenocarcinoma (PDAC). CTCs and the CXCR4 expression were detected...
8.
Yan S, Chen L, Zhuang H, Yang H, Yang Y, Zhang N, et al.
Int J Biol Sci
. 2024 Jun;
20(8):3046-3060.
PMID: 38904018
Hepatocellular carcinoma (HCC) is a deadly malignancy with limited treatment options. As a first-line treatment for advanced HCC, Lenvatinib has been applicated in clinic since 2018. Resistance to Lenvatinib, however,...
9.
Liu X, Huang Z, Chen Q, Chen K, Liu W, Liu G, et al.
Cell Death Discov
. 2024 May;
10(1):262.
PMID: 38811540
The mechanism of hypoxia in chemoresistance of pancreatic ductal adenocarcinoma (PDAC) remains elusive. In this study, we revealed the essential role of miR-485-3p in PDAC, particularly its impact on cancer...
10.
Zhang J, Duan X, Chen X, Zhang Z, Sun H, Shou J, et al.
J Nucl Med
. 2024 May;
65(Suppl 1):12S-18S.
PMID: 38719240
Nectin cell adhesion molecule 4 (nectin-4) is a transmembrane protein overexpressed on a variety of cancers and plays an important role in oncogenic and metastatic processes. The nectin-4-targeted antibody-drug conjugate...